BackRegulus Therapeutics Overview

Regulus Therapeutics Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$6.82M
12.9% YoY

As of Mar 31, 2025

Annual R&D Expenses (TTM)

$36.15M
62.74% YoY

Trailing 12 months ending Mar 31, 2025

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Regulus Therapeutics (RGLS) FAQ

Stockcircle tracks research & development for Regulus Therapeutics (RGLS), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Regulus Therapeutics's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main RGLS overview so you can move from this figure to the surrounding analysis quickly.